We confirmed that the percentages of the two subsets expressing CD16 (intermediate and non-classical) were significantly higher in CLL cases than in PBMCs from normal donors, and we found a direct correlation between the percentage of intermediate monocytes and the levels of bone erosion. The gene discussed is FCGR3A; the disease is B-cell chronic lymphocytic leukemia.